Page 36 - 中国全科医学2022-11
P. 36
http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·1313·
由于研究对象、数据来源、估计方法的不同,不同 2021,12(1):1533. DOI:10.1038/s41467-021-21710-6.
研究对 COVID-19 潜伏期的估计结果可能存在差异,但 [12]BACKER J A,KLINKENBERG D,WALLINGA J. Incubation
period of 2019 novel coronavirus (2019-nCoV) infections
潜伏期的判定依然是追溯传染源,确定密切接触者的留
among travellers from Wuhan,China,20–28 January
验、检疫和医学观察期限的依据,对其进行研究具有重
2020[J]. Eurosurveillance,2020,25(5):2000062. DOI:
要的公共卫生学意义。 10.2807/1560-7917.es.2020.25.5.2000062.
作者贡献:吴俣负责文献查询、数据收集和论文起 [13]LAUER S A,GRANTZ K H,BI Q F,et al. The incubation period
草;刘民对研究命题的提出、设计,负责最终版本修订, of coronavirus disease 2019 (COVID-19) from publicly reported
对论文负责。 confirmed cases:estimation and application[J]. Ann Intern
Med,2020,172(9):577-582. DOI:10.7326/M20-0504.
本文无利益冲突。
[14]YANG L,DAI J Y,ZHAO J,et al. Estimation of incubation
参考文献
period and serial interval of COVID-19:analysis of 178 cases and
[1]W HO. Coronav irus (COVID-19) Das hboard[EB/
131 transmission chains in Hubei Province,China[J]. Epidemiol
OL].[2022-02-05]. https://covid19.who.int/.
Infect,2020,148:e117. DOI:10.1017/S0950268820001338.
[2]WHO. Tracking SARS-CoV-2 variants[EB/OL].(2021-12-
[15]PATRIKAR S R,KOTWAL A,BHATTI V K,et al. Incubation
06) [2022-02-06]. https://www.who.int/en/activities/tracking- period and reproduction number for novel coronavirus 2019
SARS-CoV-2-variants/.
(COVID-19) infections in India[J]. Asia Pac J Public Health,
[3]HE X,LAU E H Y,WU P,et al. Temporal dynamics in viral
2020,32(8):458-460. DOI:10.1177/1010539520956427.
shedding and transmissibility of COVID-19[J]. Nat Med,2020,
[16]BÖHMER M M,BUCHHOLZ U,CORMAN V M,et al.
26(5):672-675. DOI:10.1038/s41591-020-0869-5. Investigation of a COVID-19 outbreak in Germany resulting from a
[4]万时雨,刘珏,刘民 . 新型冠状病毒肺炎潜伏期的研究进展[J].
single travel-associated primary case:a case series[J]. Lancet
科学通报,2021,66(15):1802-1811.
Infect Dis,2020,20(8):920-928. DOI:10.1016/S1473-3099(20)
WAN S Y,LIU J,LIU M. Progress on the incubation period of
30314-5.
COVID-19[J]. Chinese Science Bulletin,2021,66(15): [17]Public Health England. Investigation of SARS-CoV-2 variants
1802-1811.
of concern:technical briefings[EB/OL]. (2021-12-17)
[5]CHAN J F,KOK K H,ZHU Z,et al. Genomic characterization
[2022-02-06]. https://www.gov.uk/government/publications/
of the 2019 novel human-pathogenic coronavirus isolated from
investigation-of-novel-sars-cov-2-variant-variant-of-
a patient with atypical pneumonia after visiting Wuhan[J]. concern-20201201.
Emerg Microbes Infect,2020,9(1):221-236. DOI:
[18]穆雪纯,李丽,王凌航 . 新型冠状病毒流行变异株的分型及
10.1080/22221751.2020.1719902.
研究进展[J]. 国际病毒学杂志,2021,28(4):336-340.
[6]WU J T,LEUNG K,LEUNG G M. Nowcasting and forecasting
DOI:10.3760/cma.j.issn.1673-4092.2021.04.018.
the potential domestic and international spread of the 2019-nCoV MU X C,LI L,WANG L H. Classifications and research progress
outbreak originating in Wuhan,China:a modelling study[J].
on prevalent SARS-CoV-2 variants[J]. Int J Virol,2021,28(4):
Lancet,2020,395(10225):689-697. DOI:10.1016/S0140-
336-340. DOI:10.3760/cma.j.issn.1673-4092.2021.04.018.
6736(20)30260-9.
[19]沈佳莹,林剑生,曹广文 . 新型冠状病毒的变异株进展:起源、
[7]GUAN W J,NI Z Y,HU Y,et al. Clinical characteristics of 变异动力与防控措施[J]. 上海预防医学,2022,34(1):
coronavirus disease 2019 in China[J]. N Engl J Med,2020,382
81-86. DOI:10.19428/j.cnki.sjpm.2022.21039.
(18):1708-1720. DOI:10.1056/nejmoa2002032.
SHEN J Y,LIN J S,CAO G W. SARS-CoV-2 variants:
[8]MEYEROWITZ E A,RICHTERMAN A,GANDHI R T,et al.
origin,drivers and prevention measures[J]. Shanghai Journal of
Transmission of SARS-CoV-2:a review of viral,host,and Preventive Medicine,2022,34(1):81-86. DOI:10.19428/j.
environmental factors[J]. Ann Intern Med,2021,174(1):
cnki.sjpm.2022.21039.
69-79. DOI:10.7326/M20-5008.
[20]WHO. COVID-19 - Global[EB/OL]. (2020-12-31) [2022-
[9]LI Q,GUAN X H,WU P,et al. Early transmission dynamics in
02-06]. https://www.who.int/emergencies/disease-outbreak-
Wuhan,China,of novel coronavirus-infected pneumonia[J]. news/item/2020-DON305.
N Engl J Med,2020,382(13):1199-1207. DOI:
[21]GRANT R,CHARMET T,SCHAEFFER L,et al. Impact of
10.1056/NEJMoa2001316.
SARS-CoV-2 Delta variant on incubation,transmission settings
[10]ZHANG J J,LITVINOVA M,WANG W,et al. Evolving
and vaccine effectiveness:results from a nationwide case-control
epidemiology and transmission dynamics of coronavirus disease study in France[J]. Lancet Reg Health Eur,2022,13:100278.
2019 outside Hubei Province,China:a descriptive and modelling
DOI:10.1016/j.lanepe.2021.100278.
study[J]. Lancet Infect Dis,2020,20(7):793-802. DOI:
[22]HOMMA Y,KATSUTA T,OKA H,et al. The incubation period
10.1016/S1473-3099(20)30230-9.
of the SARS-CoV-2 B1.1.7 variant is shorter than that of other
[11]HU S X,WANG W,WANG Y,et al. Infectivity,susceptibility, strains[J]. J Infect,2021,83(2):e15-17. DOI:10.1016/j.
and risk factors associated with SARS-CoV-2 transmission under
jinf.2021.06.011.
intensive contact tracing in Hunan,China[J]. Nat Commun, (下转第1319页)